OFAC compliance

Healthcare and life sciences companies face a distinct OFAC compliance pressure point: sanctions exposure runs through drug supply chains, clinical trial partnerships, and medical device distribution in ways that generic compliance programs rarely capture. The U.S. Department of the Treasury's Office of Foreign Assets Control maintains sector-specific enforcement expectations, and the U.S. Department of Justice has coordinated with OFAC on voluntary self-disclosure outcomes that directly affect how life sciences firms calculate penalty risk. SDN list hits tied to foreign contract manufacturers and API suppliers have driven enforcement actions in this sector before, and that pattern has not gone quiet.